Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2017

Open Access 01-12-2017 | Review

Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?

Authors: Constantin Dreher, Daniel Habermehl, Oliver Jäkel, Stephanie E. Combs

Published in: Radiation Oncology | Issue 1/2017

Login to get access

Abstract

Pancreatic cancer, especially in case of locally advanced stage has a poor prognosis. Radiotherapy in general can lead to tumor volume reduction, but further improvements, such as ion beam therapy have to be promoted in order to enable dose escalation, which in turn results in better local control rates and downsizing of the tumor itself. Ion beam therapy with its highly promising physical properties is also accompanied by distinct inter- and intrafractional challenges in case of robustness. First clinical results are promising, but further research in motion mitigation and biological treatment planning is necessary, in order to determine the best clinical rationales and conditions of ion beam therapy of pancreatic cancer. This review summarizes the current knowledge and studies on ion beam therapy of pancreatic cancer.
Literature
1.
Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.CrossRefPubMedPubMedCentral
2.
Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P, et al. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 2012;7:28.CrossRefPubMedPubMedCentral
3.
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801–10.CrossRefPubMedPubMedCentral
4.
Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, et al. Preoperative modified FOLFIRINOX treatment followed by Capecitabine-based Chemoradiation for borderline Resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151:e161137.CrossRefPubMedPubMedCentral
5.
Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E, Kooby D, Maithel SK, Sarmiento JM, Landry J, El-Rayes BF. A phase 1 study of stereotactic body radiation therapy dose escalation for borderline Resectable pancreatic cancer after modified FOLFIRINOX (NCT01446458). Int J Radiat Oncol Biol Phys. 2016;96:296–303.CrossRefPubMed
6.
Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D, Landry J. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123(18):3486-493.
7.
Qing SW, Ju XP, Cao YS, Zhang HJ. Dose escalation of stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study. Radiat Oncol. 2017;12:6.CrossRefPubMedPubMedCentral
8.
Panje C, Andratschke N, Brunner TB, Niyazi M, Guckenberger M. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : literature review and practice recommendations of the DEGRO working group on stereotactic radiotherapy. Strahlenther Onkol. 2016;192:875–85.CrossRefPubMed
9.
Habermehl D, Henkner K, Ecker S, Jakel O, Debus J, Combs SE. Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy. J Radiat Res. 2013;54(Suppl 1):i61–8.CrossRefPubMedPubMedCentral
10.
Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, et al. Tolerability and long-term outcomes of dose-painted Neoadjuvant Chemoradiation to regions of vessel involvement in borderline or locally advanced pancreatic cancer. Am J Clin Oncol. 2017;
11.
Kishi T, Matsuo Y, Nakamura A, Nakamoto Y, Itasaka S, Mizowaki T, Togashi K, Hiraoka M. Comparative evaluation of respiratory-gated and ungated FDG-PET for target volume definition in radiotherapy treatment planning for pancreatic cancer. Radiother Oncol. 2016;120:217–21.CrossRefPubMed
12.
Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U, Nestle U, Baltas D, Grosu AL, Brunner TB. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : a toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlenther Onkol. 2017;193:433–43.CrossRefPubMed
13.
Suit H, DeLaney T, Goldberg S, Paganetti H, Clasie B, Gerweck L, Niemierko A, Hall E, Flanz J, Hallman J, Trofimov A. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol. 2010;95:3–22.CrossRefPubMed
14.
El Shafie RA, Habermehl D, Rieken S, Mairani A, Orschiedt L, Brons S, Haberer T, Weber KJ, Debus J, Combs SE. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. J Radiat Res. 2013;54(Suppl 1):i113–9.CrossRefPubMedPubMedCentral
15.
Habermehl D, Ilicic K, Dehne S, Rieken S, Orschiedt L, Brons S, Haberer T, Weber KJ, Debus J, Combs SE. The relative biological effectiveness for carbon and oxygen ion beams using the raster-scanning technique in hepatocellular carcinoma cell lines. PLoS One. 2014;9:e113591.CrossRefPubMedPubMedCentral
16.
Oonishi K, Cui X, Hirakawa H, Fujimori A, Kamijo T, Yamada S, Yokosuka O, Kamada T. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol. 2012;105:258–65.CrossRefPubMed
17.
Prescribing, recording, and reporting proton-beam therapy. pp. NP: International Commission on Radiation Units and Measurements; 2007:NP.
18.
Georgakilas AG, O'Neill P, Stewart RD. Induction and repair of clustered DNA lesions: what do we know so far? Radiat Res. 2013;180:100–9.CrossRefPubMed
19.
Dehne S, Fritz C, Rieken S, Baris D, Brons S, Haberer T, Debus J, Weber KJ, Schmid TE, Combs SE, Habermehl D. Combination of photon and carbon ion irradiation with targeted therapy substances Temsirolimus and Gemcitabine in Hepatocellular carcinoma cell lines. Front Oncol. 2017;7:35.CrossRefPubMedPubMedCentral
20.
Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ, Vierra M. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000;48:919–22.CrossRefPubMed
21.
Bassler N, Toftegaard J, Luhr A, Sorensen BS, Scifoni E, Kramer M, Jakel O, Mortensen LS, Overgaard J, Petersen JB. LET-painting increases tumour control probability in hypoxic tumours. Acta Oncol. 2014;53:25–32.CrossRefPubMed
22.
Schneider RA, Vitolo V, Albertini F, Koch T, Ares C, Lomax A, Goitein G, Hug EB. Small bowel toxicity after high dose spot scanning-based proton beam therapy for paraspinal/retroperitoneal neoplasms. Strahlenther Onkol. 2013;189:1020–5.CrossRefPubMed
23.
Shinoto M, Shioyama Y, Matsunobu A, Okamoto K, Suefuji H, Toyama S, Honda H, Kudo S. Dosimetric analysis of upper gastrointestinal ulcer after carbon-ion radiotherapy for pancreatic cancer. Radiother Oncol. 2016;120:140–4.CrossRefPubMed
24.
Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2014;49:1074–80.CrossRefPubMed
25.
Sihver L, Tsao CH, Silberberg R, Barghouty AF, Kanai T. Calculations of depth-dose distributions, cross sections and momentum loss. Adv Space Res. 1996;17:105–8.CrossRefPubMed
26.
Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T, et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:201–10.CrossRefPubMed
27.
Mori S, Shinoto M, Yamada S. Four-dimensional treatment planning in layer-stacking boost irradiation for carbon-ion pancreatic therapy. Radiother Oncol. 2014;111:258–63.CrossRefPubMed
28.
Kawashiro S, Mori S, Yamada S, Miki K, Nemoto K, Tsuji H, Kamada T. Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: simulation with four-dimensional computed tomography. Br J Radiol. 2017;90:20160790.CrossRefPubMed
29.
Miki K, Mori S, Shiomi M, Yamada S. Gated carbon-ion scanning treatment for pancreatic tumour with field specific target volume and organs at risk. Phys Med. 2016;32:1521–8.CrossRefPubMed
30.
Shiomi M, Mori S, Shinoto M, Nakayama Y, Kamada T, Yamada S. Comparison of carbon-ion passive and scanning irradiation for pancreatic cancer. Radiother Oncol. 2016;119:326–30.CrossRefPubMed
31.
Haberer T, Becher W, Schardt D, Kraft G. Magnetic scanning system for heavy ion therapy. Nucl Inst Methods Phys Res Section A. 1993;330:296–305.CrossRef
32.
Kramer M, Scholz M. Treatment planning for heavy-ion radiotherapy: calculation and optimization of biologically effective dose. Phys Med Biol. 2000;45:3319–30.CrossRefPubMed
33.
Scholz M, Kellerer AM, Kraft-Weyrather W, Kraft G. Computation of cell survival in heavy ion beams for therapy. The model and its approximation. Radiat Environ Biophys. 1997;36:59–66.CrossRefPubMed
34.
Giovannini G, Bohlen T, Cabal G, Bauer J, Tessonnier T, Frey K, Debus J, Mairani A, Parodi K. Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios. Radiat Oncol. 2016;11:68.CrossRefPubMedPubMedCentral
35.
Held KD, Kawamura H, Kaminuma T, Paz AE, Yoshida Y, Liu Q, Willers H, Takahashi A. Effects of charged particles on human tumor cells. Front Oncol. 2016;6:23.CrossRefPubMedPubMedCentral
36.
Habermehl D, Brecht IC, Bergmann F, Welzel T, Rieken S, Werner J, Schirmacher P, Buchler MW, Debus J, Combs SE. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Radiat Oncol. 2013;8:27.CrossRefPubMedPubMedCentral
37.
ICRU: PRESCRIBING, RECORDING, AND REPORTING PROTON-BEAM THERAPY: CONTENTS. Journal of the ICRU 2007; 7:NP.
38.
Shinoto M, Yamada S, Yasuda S, Imada H, Shioyama Y, Honda H, Kamada T, Tsujii H, Saisho H. Working Group for Pancreas C: phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer. 2013;119:45–51.CrossRefPubMed
39.
Dreher C, Habermehl D, Ecker S, Brons S, El-Shafie R, Jakel O, Debus J, Combs SE. Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. Radiat Oncol. 2015;10:237.CrossRefPubMedPubMedCentral
40.
Batista V, Richter D, Combs SE, Jakel O. Planning strategies for inter-fractional robustness in pancreatic patients treated with scanned carbon therapy. Radiat Oncol. 2017;12:94.CrossRefPubMedPubMedCentral
41.
Nill S, Bortfeld T, Oelfke U. Inverse planning of intensity modulated proton therapy. Z Med Phys. 2004;14:35–40.CrossRefPubMed
42.
Oelfke U, Bortfeld T. Intensity modulated radiotherapy with charged particle beams: studies of inverse treatment planning for rotation therapy. Med Phys. 2000;27:1246–57.CrossRefPubMed
43.
44.
Paganetti H. Significance and implementation of RBE variations in proton beam therapy. Technol Cancer Res Treat. 2003;2:413–26.CrossRefPubMed
45.
Nieder C, Grosu AL, Andratschke NH, Molls M. Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Radiat Oncol Biol Phys. 2005;61:851–5.CrossRefPubMed
46.
Sahgal A, Ma L, Weinberg V, Gibbs IC, Chao S, Chang UK, Werner-Wasik M, Angelov L, Chang EL, Sohn MJ, et al. Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:107–16.CrossRefPubMed
47.
Sahgal A, Weinberg V, Ma L, Chang E, Chao S, Muacevic A, Gorgulho A, Soltys S, Gerszten PC, Ryu S, et al. Probabilities of radiation Myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys. 2013;85:341–7.CrossRefPubMed
48.
Dreher C, Scholz C, Pommer M, Brons S, Prokesch H, Ecker S, Debus J, Jakel O, Combs SE, Habermehl D. Optimization of carbon ion treatment plans by integrating tissue specific alpha/beta-values for patients with non-Resectable pancreatic cancer. PLoS One. 2016;11:e0164473.CrossRefPubMedPubMedCentral
49.
Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, Miften M. Radiation dose–volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76:S101–7.CrossRefPubMed
50.
Sachsman SR, Charles Nichols J, Morris CG, Zaiden R, Johnson EA, Awad Z, Bose D, Ho MW, Huh SN, Li Z, et al. Proton therapy and concomitant Capecitabine for non-metastatic Unresectable pancreatic Adenocarcinoma. Int J Particle Therapy. 2014;1:692–701.CrossRef
51.
Nichols RC Jr, Hoppe BS. RE: Takatori K, Terashima K, Yoshida R, Horai a, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2013; (E-pub only). J Gastrointest Oncol. 2013;4:E33–4.PubMedPubMedCentral
52.
Bahl A, Kapoor R, Bhattacharya T, Sharma SC. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. In Regard to Kelly et al. Int J Radiat Oncol Biol Phys. 2014;88:237.CrossRefPubMed
53.
54.
Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M, Krishnan S, Delclos ME, Crane CH. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85:e143–9.CrossRefPubMed
55.
Terashima K, Demizu Y, Hashimoto N, Jin D, Mima M, Fujii O, Niwa Y, Takatori K, Kitajima N, Sirakawa S, et al. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol. 2012;103:25–31.CrossRefPubMed
56.
Combs SE, Kalbe A, Nikoghosyan A, Ackermann B, Jakel O, Haberer T, Debus J. Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol. 2011;98:63–7.CrossRefPubMed
57.
Habermehl D, Wagner M, Ellerbrock M, Buchler MW, Jakel O, Debus J, Combs SE. Reirradiation using carbon ions in patients with locally recurrent rectal cancer at HIT: first results. Ann Surg Oncol. 2014;
58.
Akimoto M, Nakamura M, Nakamura A, Mukumoto N, Kishi T, Goto Y, Mizowaki T, Hiraoka M. Inter- and Intrafractional variation in the 3-dimensional positions of pancreatic tumors due to respiration under real-time monitoring. Int J Radiat Oncol Biol Phys. 2017;98:1204–11.CrossRefPubMed
59.
Kessel KA, Jager A, Habermehl D, Ruppell J, Bendl R, Debus J, Combs SE. Changes in gross tumor volume and organ motion analysis during Neoadjuvant Radiochemotherapy in patients with locally advanced pancreatic cancer using an in-house analysis system. Technol Cancer Res Treat. 2016;15:348–54.CrossRefPubMed
60.
Fontana G, Riboldi M, Gianoli C, Chirvase CI, Villa G, Paganelli C, Summers PE, Tagaste B, Pella A, Fossati P, et al. MRI quantification of pancreas motion as a function of patient setup for particle therapy -a preliminary study. J Appl Clin Med Phys. 2016;17:1–16.CrossRef
61.
Lovelock DM, Zatcky J, Goodman K, Yamada Y. The effectiveness of a pneumatic compression belt in reducing respiratory motion of abdominal tumors in patients undergoing stereotactic body radiotherapy. Technol Cancer Res Treat. 2014;13:259–67.CrossRefPubMed
62.
Miki K, Fukahori M, Kumagai M, Yamada S, Mori S. Effect of patient positioning on carbon-ion therapy planned dose distribution to pancreatic tumors and organs at risk. Phys Med. 2016;33:38-46.
63.
Kumagai M, Hara R, Mori S, Yanagi T, Asakura H, Kishimoto R, Kato H, Yamada S, Kandatsu S, Kamada T. Impact of intrafractional bowel gas movement on carbon ion beam dose distribution in pancreatic radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1276–81.CrossRefPubMed
64.
Steitz J, Naumann P, Ulrich S, Haefner MF, Sterzing F, Oelfke U, Bangert M. Worst case optimization for interfractional motion mitigation in carbon ion therapy of pancreatic cancer. Radiat Oncol. 2016;11:134.CrossRefPubMedPubMedCentral
65.
De Ruysscher D, Sterpin E, Haustermans K, Depuydt T. Tumour movement in proton therapy: solutions and remaining questions: a review. Cancers (Basel). 2015;7:1143–53.CrossRef
66.
Richter D, Saito N, Chaudhri N, Hartig M, Ellerbrock M, Jakel O, Combs SE, Habermehl D, Herfarth K, Durante M, Bert C. Four-dimensional patient dose reconstruction for scanned ion beam therapy of moving liver tumors. Int J Radiat Oncol Biol Phys. 2014;89:175–81.CrossRefPubMed
67.
Taniguchi CM, Murphy JD, Eclov N, Atwood TF, Kielar KN, Christman-Skieller C, Mok E, Xing L, Koong AC, Chang DT. Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85:1090–5.CrossRefPubMed
68.
Campbell WG, Jones BL, Schefter T, Goodman KA, Miften M. An evaluation of motion mitigation techniques for pancreatic SBRT. Radiother Oncol. 2017;124:168–73.CrossRefPubMed
69.
Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose–volume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010;76:S42–9.CrossRefPubMed
70.
Cattaneo GM, Passoni P, Sangalli G, Slim N, Longobardi B, Mancosu P, Bettinardi V, Di Muzio N, Calandrino R. Internal target volume defined by contrast-enhanced 4D-CT scan in unresectable pancreatic tumour: evaluation and reproducibility. Radiother Oncol. 2010;97:525–9.CrossRefPubMed
71.
Liu F, Erickson B, Peng C, Li XA. Characterization and management of interfractional anatomic changes for pancreatic cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:e423–9.CrossRefPubMed
72.
Richter D, Graeff C, Jakel O, Combs SE, Durante M, Bert C. Residual motion mitigation in scanned carbon ion beam therapy of liver tumors using enlarged pencil beam overlap. Radiother Oncol. 2014;113:290–5.CrossRefPubMed
73.
Schulz-Ertner D, Debus J: Hadronentherapie. In Strahlentherapie. Edited by Wannenmacher M, Wenz F, Debus J: Springer Berlin Heidelberg; 2013: 207–224.
74.
Nichols RC Jr, George TJ, Zaiden RA Jr, Awad ZT, Asbun HJ, Huh S, Ho MW, Mendenhall NP, Morris CG, Hoppe BS. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncol. 2013;52:498–505.CrossRefPubMed
75.
Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, Adams J, Yeap B, Winrich B, DeLaney TF, Fernandez-Del Castillo C. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys. 2011;79:151–7.CrossRefPubMed
76.
Okada T, Kamada T, Tsuji H, Mizoe JE, Baba M, Kato S, Yamada S, Sugahara S, Yasuda S, Yamamoto N, et al. Carbon ion radiotherapy: clinical experiences at National Institute of radiological science (NIRS). J Radiat Res. 2010;51:355–64.CrossRefPubMed
77.
Shinoto M, Yamada S, Terashima K, Yasuda S, Shioyama Y, Honda H, Kamada T, Tsujii H, Saisho H. Carbon ion radiation therapy with concurrent Gemcitabine for patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;95:498–504.CrossRefPubMed
Metadata
Title
Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?
Authors
Constantin Dreher
Daniel Habermehl
Oliver Jäkel
Stephanie E. Combs
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0945-2

Other articles of this Issue 1/2017

Radiation Oncology 1/2017 Go to the issue

Research

Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center

Correction

Correction to: Improved plan quality with automated radiotherapy planning for whole brain with hippocampus sparing: a comparison to the RTOG 0933 trial

Research

The impact of dual energy CT imaging on dose calculations for pre-clinical studies

Research

Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer

Research

Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?

Research

Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer